CONSIDER THE IMPACT OF ORAL STEROIDS
Although oral corticosteroids (OCS) have an established role in postoperative care, and in many cases may be the right treatment for patients with CRS, it’s important to consider its challenges.1,17 Even short courses of OCS have been associated with systemic adverse reactions, especially when administered repeatedly.18
Not all steroids are created equal
Mometasone furoate (MF) is a next-generation corticosteroid designed for improved efficacy and safety.19
The PROPEL sinus implants are indicated to maintain patency and locally deliver steroid to the sinus mucosa in patients ≥18 years of age after sinus surgery: PROPEL for the ethmoid sinus, PROPEL Mini for the ethmoid sinus/frontal sinus opening, and PROPEL Contour for the frontal/maxillary sinus ostia.
Mometasone furoate has not been specifically studied on Type 2 inflammation, but PROPEL has been studied on both patients with CRSwNP and CRSsNP.